QIAGEN Gains FDA Clearance for GI Panels on Automated Testing System
Event summary
- QIAGEN received FDA clearance for all QIAstat-Dx Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system.
- The QIAstat-Dx Rise system, launched in September 2025, processes up to 160 tests daily with a throughput of 16 samples per batch.
- The clearance expands QIAGEN’s U.S. portfolio to six panels cleared for the QIAstat-Dx family, marking the ninth FDA clearance in 24 months.
- The system delivers results in approximately one hour using real-time PCR technology and requires less than one minute of hands-on time per test.
The big picture
QIAGEN's clearance for GI panels on the QIAstat-Dx Rise system strengthens its position in the rapidly growing syndromic testing market, which is driven by the need for faster and more comprehensive pathogen identification. The move to higher-throughput automation addresses the increasing demand for testing capacity in clinical laboratories, and the consolidation of respiratory and GI testing on a single platform offers operational efficiencies. This expansion builds on QIAGEN’s broader ‘Sample to Insight’ strategy, integrating sample preparation, molecular testing, and data interpretation.
What we're watching
- Market Adoption
- The pace at which laboratories adopt the QIAstat-Dx Rise system will determine the extent of QIAGEN’s revenue growth in the syndromic testing market, particularly given the existing installed base of QIAstat-Dx systems.
- Competitive Landscape
- How competitors respond to QIAGEN’s expanded offering and automation capabilities will shape the long-term dynamics of the syndromic testing market, potentially leading to price pressure or innovation races.
- Panel Expansion
- The speed at which QIAGEN expands the panel offerings for the QIAstat-Dx Rise system will be a key indicator of its commitment to the platform and its ability to capture a broader share of the syndromic testing market.
Related topics